• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Allurion Technologies Inc. (Amendment)

    4/17/24 6:57:43 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care
    Get the next $ALUR alert in real time by email
    SC 13D/A 1 p24-1471sc13da.htm ALLURION TECHNOLOGIES INC.

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D/A
    (Amendment No. 1)

    Under the Securities Exchange Act of 1934

    ALLURION TECHNOLOGIES, INC.
    (Name of Issuer)

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

    02008G102
    (CUSIP Number)

    RTW Investments, LP
    Attn: Roderick Wong, M.D.
    40 10th Avenue, Floor 7
    New York, New York 10014
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    April 16, 2024
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     

    CUSIP No. 02008G102
    1.

    Name of Reporting Person

    RTW Investments, LP

    2.

    Check the Appropriate Box if a Member of a Group

    (a) ¨ (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    AF

    5. Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)
    6.

    Citizenship or Place of Organization

    Delaware

     

     

     

     

    Number of Shares Beneficially Owned By Each Reporting Person with

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    3,936,903 (including 479,196 shares underlying the Notes (as defined below)).

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    3,936,903 (including 479,196 shares underlying the Notes).

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,936,903 (including 479,196 shares underlying the Notes).

    12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
    13.

    Percent of Class Represented by Amount in Row (11)

    8.1%(1)

    14.

    Type of Reporting Person

    PN, IA

           

    (1) Percentage based upon 47,852,203 shares of the Company’s Common Stock outstanding as of March 22, 2024, as set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and assumes the conversion of the Notes up to the Conversion Cap (as defined below).

     
     

     

    CUSIP No. 02008G102
    1.

    Name of Reporting Person

    Roderick Wong, M.D.

    2.

    Check the Appropriate Box if a Member of a Group

    (a) ¨ (b) ¨

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    AF

    5. Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)
    6.

    Citizenship or Place of Organization

    United States of America

     

     

     

     

    Number of Shares Beneficially Owned By Each Reporting Person with

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    3,936,903 (including 479,196 shares underlying the Notes).

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    3,936,903 (including 479,196 shares underlying the Notes).

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,936,903 (including 479,196 shares underlying the Notes).

    12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares ¨
    13.

    Percent of Class Represented by Amount in Row (11)

    8.1%(1)

    14.

    Type of Reporting Person

    IN, HC

           

    (1) Percentage based upon 47,852,203 shares of the Company’s Common Stock outstanding as of March 22, 2024, as set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and assumes the conversion of the Notes up to the Conversion Cap.

     
     

    The following constitutes Amendment No. 1 (“Amendment No. 1”) to the initial statement on Schedule 13D, filed on August 11, 2023 (the “Initial Schedule 13D”) by the undersigned. This Amendment No. 1 amends the Initial Schedule 13D as specifically set forth herein (the Initial Schedule 13D as amended by this Amendment No. 1, the “Schedule 13D”). Capitalized terms used in this Amendment No. 1 and not otherwise defined herein have the meanings given to them in the Initial Schedule 13D.

    Item 3. Source and Amount of Funds or Other Consideration.

    Item 3 of the Schedule 13D is hereby amended to add the following:

    The source of funds used for the purchase of the Notes was the working capital of the RTW Funds. The aggregate purchase price of the Notes reported herein was approximately $48 million.

    Item 4. Purpose of Transaction.

    Item 4 of the Schedule 13D is hereby amended to add the following:

     

    Note Purchase Agreement

     

    On April 14, 2024, Company, RTW Investments, as agent for the purchasers (the “Purchasers”) party thereto from time to time (in such capacity, the “Principal Purchaser”), and Acquiom Agency Services LLC, as collateral agent for the Purchasers and the Principal Purchaser, entered into a Note Purchase Agreement (the “Original Note Purchase Agreement” and, as amended by the Amendment (as defined herein), the “Amended Note Purchase Agreement”). On April 16, 2024, the Company, the Principal Purchaser, the Purchasers and Acquiom entered into the First Amendment to the Original Note Purchase Agreement (the “Amendment”). Pursuant to the Amended Note Purchase Agreement, the Company issued and sold $48 million aggregate principal amount of convertible senior secured notes (the “Notes”) to the Purchasers in a private placement transaction. The Purchasers are RTW Funds.

     

    The Notes will bear interest at the annual rate of 6.0%, which is payable quarterly in cash or, at the Company’s option, in kind for the first three years. The maturity date for the Notes will be April 16, 2031. The Notes are guaranteed by Allurion Technologies, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Allurion Opco”), and certain other current and future subsidiaries of the Company and are secured by substantially all the assets of the Company and the guarantors.

     

    The Notes are convertible into shares of the Company's Common Stock at the Purchaser’s election at any time after the earliest of (i) the date on which Stockholder Approval (as defined below) is obtained, (ii) December 31, 2025, (iii) the date of a Fundamental Change Company Notice (as defined in the Note Purchase Agreement), and (iv) the Make-Whole Fundamental Change Effective Date (as defined in the Amended Note Purchase Agreement), subject to certain terms and limitations in the Amended Note Purchase Agreement, based on the higher of (x) an initial conversion rate of 307.0797 shares of Common Stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $3.26 per share, which represents a 35% premium to the trailing 30 day volume weighted average price (“VWAP”) of the Company's Common Stock on the New York Stock Exchange (the “NYSE”) as of the close of business on April 12, 2024 and (y) a 35% conversion premium to the lowest price per share in an equity financing for capital raising purposes ending on the date on which the Company has raised aggregate gross offering proceeds of at least $15,000,000 (the “Next Equity Financing”).

     

    Although the initial conversion price based on clause (x) above for the Notes is above NYSE’s “Minimum Price” (as such term is defined in Section 312.03 of the NYSE Listed Company Manual), it is subject to a reset provision at the time of the Next Equity Financing that could result in the conversion price falling below such Minimum Price. Therefore, the Amended Note Purchase Agreement provides that unless and until requisite approval of the Company’s stockholders is obtained (“Stockholder Approval”), the Company will not deliver Common Stock upon conversion of the Notes in excess of 1% of the number of shares of the Company’s Common Stock outstanding as of April 14, 2024 (the “Conversion Cap”). The Company is required to include a proposal in its definitive proxy statement on Schedule 14A seeking Stockholder Approval no later than December 31, 2025, and if the Company does not obtain Stockholder Approval at such meeting, it shall call a special meeting of stockholders each 90-day period thereafter at least two times, and thereafter at each subsequent annual meeting until Stockholder Approval is obtained or the Notes are no longer outstanding; provided, that shares of Common Stock issued upon conversion of the Notes prior to obtaining Stockholder Approval shall not be entitled to vote in favor of Stockholder Approval.

     

    Subject to specified conditions, on or after April 16, 2028, the Notes are redeemable by the Company at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. Pursuant to the terms of the Amended Note Purchase Agreement, each Purchaser is subject to a beneficial ownership conversion limitation such that no Purchaser shall be permitted to convert Notes to the extent it would result in such Purchaser and its affiliates beneficially owning more than 9.99% of the Company’s Common Stock.

     

    Pursuant to the terms of the Amended Note Purchase Agreement, RTW Investments will be entitled to appoint a non-voting board observer to the Company’s board of directors (the “Board”), and the Company shall include an additional director nominee in the Company’s proxy statement for the election of the Class I directors at the Company’s 2024 annual meeting of stockholders, with the recommendation of the Board to vote in favor of such additional nominee as well as the “RTW Designated Director” (as defined in the Investor Rights Agreement). Such additional director nominee shall go through the Company’s director nomination process led by the Nominating and Corporate Governance Committee of the Board. RTW Investments shall have the right to approve such additional nominee, with such approval not to be unreasonably withheld.

     

    The Amended Note Purchase Agreement contains customary terms and covenants, including negative covenants, such as limitations on indebtedness, liens, disposition of assets and mergers. The Amended Note Purchase Agreement also contains financial maintenance covenants, which require (i) the Company and Allurion Opco to maintain not less than $12,500,000 in unrestricted cash in controlled accounts in the U.S. at all times, (ii) the Company to receive minimum trailing twelve-month consolidated Revenue (as defined in the Amended Note Purchase Agreement) of certain amounts set forth in the Amended Note Purchase Agreement, tested quarterly beginning with the twelve-month period ending March 31, 2025, and (iii) the Company's and its subsidiaries’ consolidated business operations outside the United States to be profitable for the trailing three-month period, tested quarterly beginning with the three-month period ending December 31, 2025. The Amended Note Purchase Agreement also contains customary events of default, including defaults related to payment compliance, material inaccuracy of representations and warranties, covenant compliance, bankruptcy and insolvency proceedings, cross-payment defaults and cross-acceleration to certain other material indebtedness agreements and judgment default.

     
     

    The foregoing description of the Original Note Purchase Agreement and the Amendment is not complete and is qualified in its entirety by reference to the complete text of the Original Note Purchase Agreement, which is filed as Exhibit 99.10 to the Schedule 13D and the Amendment, which is filed as Exhibit 99.11 to the Schedule 13D.

    Amendment to Revenue Interest Financing Agreement

    On April 14, 2024, the Revenue Interest Financing Agreement (the “Original RIFA”) was amended pursuant to the Omnibus Amendment (the “RIFA Amendment”), by and among the Company, Allurion Opco, Allurion Australia Pty Ltd, a proprietary limited company organized under the laws of Australia and a wholly owned subsidiary of the Company, the original investor in the Revenue Interest Financing Agreement and RTW Investments, to reflect certain modifications agreed between the parties thereto in connection with the Purchasers’ purchase of the Notes and the refinancing of the Fortress Credit Agreement. Among other things, the RIFA Amendment waived the existing event of default under the Original RIFA, increased the rate of revenue interest payments to be paid to RTW Investments on all current and future products and digital solutions developed and to be developed by the Company (the “Royalty Rate”) for net sales under $100 million prior to December 31, 2026 payable to RTW Investments from 6% to 12%, and increased the Royalty Rate on net sales in excess of $100 million on or after January 1, 2027 payable to RTW Investments from 10% to 12%, subject to the terms and conditions of the RIFA Amendment.

    The foregoing description of the RIFA Amendment is not complete and is qualified in its entirety by reference to the complete text of the RIFA Amendment, which is filed as Exhibit 99.12 to the Schedule 13D.

    Amendment to RTW Investments Side Letter

    On April 14, 2024, the Company, Allurion Opco and the RTW Funds entered into the First Amendment to Amended and Restated Letter Agreement (the “Side Letter Amendment”) to the Amended and Restated RTW Side Letter (the “Existing Side Letter”) to reflect certain modifications to the Existing Side Letter in connection with the Purchasers’ purchase of the Notes. The Side Letter Amendment provides, among other things, that the RTW Funds may make a single election in certain circumstances to convert up to $7,500,000 of the purchase price that the Additional RIFA Investors paid for certain equity interests in the Company into an amount of financing provided by the RTW Funds to Allurion Opco pursuant to an additional revenue interest financing agreement with Allurion Opco.

     

    The foregoing description of the Side Letter Amendment is not complete and is qualified in its entirety by reference to the complete text of the Side Letter Amendment, which is filed as Exhibit 99.13 to the Schedule 13D.

     

    Item 5. Interest in Securities of the Issuer.

    Item 5 is hereby amended and restated as follows:

    (a)       The aggregate percentage of shares of Common Stock reported to be beneficially owned by the Reporting Persons is based upon 47,852,203 shares of Common Stock outstanding as of March 22, 2024, as reported by the Company in its Annual Report on Form 10-K for the year ended December 31, 2023, and assumes the conversion of the Notes up to the Conversion Cap.

     
     

     

    (b)        See rows (7) through (10) of the cover page to this Amendment No. 1 for the number of shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

    (c)        The Reporting Persons did not effect any transactions with respect to the Shares during the past sixty (60) days.

    (d)       No person, other than the Reporting Persons and the RTW Funds, has the right to receive or the power to direct the receipt of dividends or proceeds of sale of the shares of Common Stock reported herein.

    (e)       Not applicable.

    Item 7. Materials to be Filed as Exhibits.

    Item 7 of the Schedule 13D is hereby amended to add the following:

    99.10 Note Purchase Agreement, dated as of April 14, 2024, by and among Allurion Technologies, Inc., RTW Investments, LP, as agent for the purchasers party thereto from time to time, and Acquiom Agency Services LLC, as collateral agent for the purchasers (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on April 17, 2024).

    99.11 First Amendment to Note Purchase Agreement, dated as of April 16, 2024, by and among Allurion Technologies, Inc., RTW Investments, LP, as agent for the purchasers party thereto from time to time, and Acquiom Agency Services LLC, as collateral agent for the purchasers (incorporated herein by reference to Exhibit 10.4 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on April 17, 2024).

    99.12 Omnibus Amendment, dated as of April 14, 2024, by and among Allurion Technologies, Inc., Allurion Technologies, LLC and certain entities that have engaged RTW Investments, LP as investment manager (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on April 17, 2024).

    99.13 First Amendment to Amended and Restated Letter Agreement, dated as of April 14, 2024, by and among Allurion Technologies, Inc., Allurion Technologies, LLC, RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Biotech Opportunities Operating Ltd. (incorporated herein by reference to Exhibit 10.3 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on April 17, 2024).

     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

    Date: April 17, 2024

     

      RTW INVESTMENTS, LP
       
       
      By: /s/ Roderick Wong, M.D.
      Name:  Roderick Wong, M.D.
      Title:    Managing Partner
       
       
      /s/ Roderick Wong, M.D.
      RODERICK WONG, M.D.
       

     

    Get the next $ALUR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ALUR

    DatePrice TargetRatingAnalyst
    11/14/2024Buy → Neutral
    Chardan Capital Markets
    10/2/2024$2.00Buy
    TD Cowen
    9/6/2024$2.00Buy
    ROTH MKM
    2/9/2024$5.00Buy
    Jefferies
    More analyst ratings

    $ALUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints

      Fourth and final module of the PMA submitted in June Supportive analyses included in final module of the PMA meet both of the pre-specified co-primary endpoints in the AUDACITY Study Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced submission of the fourth and final module of the Pre-Market Approval (PMA) application to the Food & Drug Administration (FDA) and additional, supportive analyses from the AUDACITY Study that meet both of the pre-specified co-primary endpoints. Topline results announced previously showed that the AUDACITY Study met its first co-primary endpoint related to responder rate at 48 weeks. Allurion Balloon su

      7/7/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

      Findings from two abstracts presented at the American Society for Metabolic & Bariatric Surgery (ASMBS) 2025 Annual Meeting reinforce the role of the AI-powered Allurion Program in delivering metabolically healthy weight loss Real-world experience in nearly 20,000 patients with the Allurion Program confirms significant fat loss while increasing lean body and muscle mass In one of the longest real-world studies of its kind, patients who followed the Allurion Program for four years maintained, on average, 89% of the weight lost during balloon therapy Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today presented two new abstracts at the Amer

      6/17/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion to Present at Jefferies Global Healthcare Conference

      Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference in New York. The live presentation will take place on Wednesday, June 4 at 3:45 p.m. ET. A webcast of the presentation will be available in the Events & Presentations section of Allurion's investor relations website. About Allurion Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world's first and only swallowable, proced

      5/29/25 4:05:00 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      5/21/25 4:15:08 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Director Rtw Investments, Lp converted options into 1,492,539 shares (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      4/17/25 6:36:58 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      4/1/25 4:15:07 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    SEC Filings

    See more
    • SEC Form S-8 filed by Allurion Technologies Inc.

      S-8 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

      6/18/25 5:10:21 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by Allurion Technologies Inc.

      424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

      5/20/25 5:04:39 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by Allurion Technologies Inc.

      424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

      5/20/25 5:02:23 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Allurion Technologies downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded Allurion Technologies from Buy to Neutral

      11/14/24 8:29:33 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • TD Cowen initiated coverage on Allurion Technologies with a new price target

      TD Cowen initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

      10/2/24 7:13:57 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • ROTH MKM initiated coverage on Allurion Technologies with a new price target

      ROTH MKM initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

      9/6/24 7:25:38 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      5/21/25 4:15:08 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      4/1/25 4:15:07 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Financials

    Live finance-specific insights

    See more
    • Allurion Reports First Quarter 2025 Financial Results and Provides Business Update

      Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update. Recent Company Highlights and Outlook Maintaining 2025 revenue guidance of approximately $30 million with a reduction of approximately 50% in operating expenses compared to 2024 First quarter revenue of $5.6 million and operating expenses of $11.4 million, a 37% decrease in operating expenses compared to prior year; adjusted operating expenses of $10.1 million, a 45% decrease compared to prior year Net operating loss of $7.3 million, a 36% reduction compared to prior year; adj

      5/14/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion to Report First Quarter 2025 Financial Results on May 14, 2025

      Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the first quarter 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay of the conferenc

      5/5/25 4:05:00 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

      Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. Recent Company Highlights and Outlook Reported initial data on the combination of the Allurion Program with low-dose GLP-1s showing optimization of muscle mass and GLP-1 adherence and announced plans to perform additional prospective studies on the combination approach Fourth quarter 2024 revenue of $5.6 million and full year revenue of $32.1 million, consistent with preannouncement on January 14, 2025 Fourth quarter 2024 operating expenses of $19

      3/26/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Leadership Updates

    Live Leadership Updates

    See more
    • Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

      Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "I believe having Keith as a sounding board as we leverage the opportunities created by GLP-1s will be a competitive advantage." Omar Ishrak, Al

      9/3/24 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial

      Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company's international commercial sales and operations functions. "We are thrilled to welcome Adrian to Allurion and add his expertise to our leadership team as we advance the company toward profitability," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "Adrian joins us at an extremely important time – where the obesity market is expandi

      8/20/24 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

      Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working closely with the Board and Executive Leadership Team. Ojas will provide strategic and execution-focused guidance aimed to help the company achieve major milestones and scale sustainably. With a 25-year track record in the health

      6/5/24 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

      SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

      11/14/24 4:43:43 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

      SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

      11/14/24 4:15:52 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Allurion Technologies Inc.

      SC 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

      10/24/24 5:19:39 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care